|
Jubilant Organosys Ltd, headquartered at NOIDA, near New
Delhi, announced today that its subsidiary Jubilant
Biosys Ltd. based in Bangalore has
developed a next generation screening solution, Legend NGSS™, that will further
enable the process of high throughput screening, accelerating global drug
discovery. The software to be launched
in the US and Europe
initially, allows scientists to
capture, store, and analyze Oracle 9i/10g based screening data with greater
flexibility, accuracy and speed.
Legend NGSS™ allows users to create rich visualization and
interactive analysis reports, including dose-response curves and scatter plot
heat maps. The novel tool allows flexible and interactive mother to daughter
plate mapping from any plate reader. This generates best-fit kinetic and time
course assays, without internal IT intervention, complete management of
compound and targeted libraries, and optimized on-the fly curve-fitting
techniques.
“This novel screening tool for scientific, pharmaceutical
and biotech communities around the world can enhance the productivity of
pharmaceutical and biotech research,” said Amit Rustagi, Head IT, Jubilant Biosys.
“This innovative product demonstrates Jubilant's strategy to
develop and provide enabling technologies to accelerate the process of Drug
Discovery and Development.” he added further.
Legend NGSS™ has been developed in collaboration with a
leading global pharmaceutical company. It is available worldwide on a
subscription basis, which includes comprehensive software support and training.
The product has generated substantial interest and response during prelaunch
activities from global pharmaceutical companies involved in drug discovery.
About Jubilant Biosys
Jubilant Biosys Ltd. (www.jubilantbiosys.com) is a
subsidiary of Jubilant Organosys Ltd., which provides integrated drug discovery
and development solutions to the global pharmaceutical industry. The 120,000
sq. ft. state of the art Jubilant
Biosys
Center in Bangalore
integrates the capabilities of over 300 scientists specializing in multiple
disciplines including biology, chemistry, structural biology, pharmacology,
molecular modeling, crystallography and information technology to support
collaborations with global pharma companies in USA,
Europe and Japan.
About Jubilant Organosys
Jubilant Organosys
Ltd. is an integrated pharmaceutical industry player, one of the largest custom
research and manufacturing services (CRAMS) and drug discovery and development
services companies out of India. The company has a presence across the
pharmaceutical value chain for products and services such as proprietary
products ,exclusive synthesis, active pharmaceutical ingredients, contract
manufacturing of sterile injectables (liquids and lyophilized) products,
non-steriles (ointments, creams and liquid) and radiopharmaceuticals, drug
discovery services, medicinal chemistry services, clinical research services
,generic dosage forms and Health Care. Jubilant Organosys has geographically
diversified manufacturing facilities at ten locations worldwide. Together,
these help Jubilant cater to 150 customers across more than 50 countries around
the world.
---ENDS---
For further information :
|
|
|
|
|
|
|
|
|
|
|
|
|
Jubilant Organosys Limited |
Jubilant Organosys Limited |
|
1-A, Sector 16-A, Institutional Area |
1-A, Sector 16-A, Institutional Area |
|
Noida - 201301 (UP) |
Noida - 201301 (UP) |
|
Ph: +91-120-4361062 |
Ph: +91-120-4361114 |
|
Mobile - +91-9810631779 |
|
|
Email:
seema_ahuja@jubl.com |
|
Disclaimer:
Statements in this
document relating to future status, events, or
circumstances, including but not limited to statements about
plans and objectives, the progress and results of research
and development, potential product characteristics and uses,
product sales potential and target dates for product launch
are forward-looking statements based on estimates and the
anticipated effects of future events on current and
developing circumstances. Such statements are subject to
numerous risks and uncertainties and are not necessarily
predictive of future results. Actual results may differ
materially from those anticipated in the forward-looking
statements. Jubilant Organosys may, from time to time, make
additional written and oral forward looking statements,
including statements contained in the company's filings with
the regulatory bodies and our reports to shareholders. The
company assumes no obligation to update forward-looking
statements to reflect actual results, changed assumptions or
other factors.
|
